Buntanetap, an experimental treatment for neurodegenerative diseases, was safe, lowered toxic protein accumulation, reduced inflammation, and improved cognition in people with Alzheimer’s disease. This was according to data from a Phase 2a trial (NCT04524351) that evaluated the investigational therapy against a placebo…

Annovis Bio’s oral therapy ANVS401 lessened the accumulation of toxic forms of amyloid-beta and tau protein — two hallmarks of Alzheimer’s disease — and led to significant improvements in cognition in patients with early Alzheimer’s, data from a Phase 2a study show. Moreover, ANVS401 levels in the blood…

Annovis Bio’s oral therapy ANVS401 (also known as Posiphen) led to significant improvements in cognition in patients with Alzheimer’s disease, according to data from the first patient group in a Phase 2a study. The improvements were also observed in patients with Parkinson’s disease enrolled in the…

Annovis Bio is seeking orphan drug status for its investigational therapy ANVS401, known as Posiphen, for treating Alzheimer’s disease in people with Down syndrome (DS-AD). The clinical-stage drug platform company has filed an application with the U.S. Food and Drug Administration (FDA) for such designation, granted to therapies for…

The first three patients have been dosed in a Phase 2a clinical trial investigating Annovis Bio‘s lead compound ANVS401 as a treatment for people with early Alzheimer’s and Parkinson’s diseases, the company said. The trial (NCT04524351) will recruit up to 68 participants at 15 sites scattered…

A Phase 2 clinical trial testing Annovis Bio’s oral therapy ANVS401 (also known as Posiphen) in people with early Alzheimer’s disease can continue without changes, according to a positive review by the study’s independent Data Safety Monitoring Board (DSMB). The DSMB reviewed safety data, enrollment, participant status,…